You are here

  • Home
  • Archive
  • Volume 82, Issue 3
  • Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment

Article info

Article menu
Download PDFPDF
Paper
Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment

Authors

  • D M Pickin aMedical Care Research Unit, School of Health and Related Research, University of Sheffield, Regent Court, 30 Regent Street, Sheffield S1 4DA, UK, bSheffield Health Economics Group, School of Health and Related Research, University of Sheffield, cSection of Clinical Pharmacology and Therapeutics, Department of Medicine and Pharmacology, University of Sheffield, dDirectorate of Policy and Public Health, Sheffield Health, Sheffield, UK PubMed articlesGoogle scholar articles
  • C J McCabe aMedical Care Research Unit, School of Health and Related Research, University of Sheffield, Regent Court, 30 Regent Street, Sheffield S1 4DA, UK, bSheffield Health Economics Group, School of Health and Related Research, University of Sheffield, cSection of Clinical Pharmacology and Therapeutics, Department of Medicine and Pharmacology, University of Sheffield, dDirectorate of Policy and Public Health, Sheffield Health, Sheffield, UK PubMed articlesGoogle scholar articles
  • L E Ramsay aMedical Care Research Unit, School of Health and Related Research, University of Sheffield, Regent Court, 30 Regent Street, Sheffield S1 4DA, UK, bSheffield Health Economics Group, School of Health and Related Research, University of Sheffield, cSection of Clinical Pharmacology and Therapeutics, Department of Medicine and Pharmacology, University of Sheffield, dDirectorate of Policy and Public Health, Sheffield Health, Sheffield, UK PubMed articlesGoogle scholar articles
  • N Payne aMedical Care Research Unit, School of Health and Related Research, University of Sheffield, Regent Court, 30 Regent Street, Sheffield S1 4DA, UK, bSheffield Health Economics Group, School of Health and Related Research, University of Sheffield, cSection of Clinical Pharmacology and Therapeutics, Department of Medicine and Pharmacology, University of Sheffield, dDirectorate of Policy and Public Health, Sheffield Health, Sheffield, UK PubMed articlesGoogle scholar articles
  • I U Haq aMedical Care Research Unit, School of Health and Related Research, University of Sheffield, Regent Court, 30 Regent Street, Sheffield S1 4DA, UK, bSheffield Health Economics Group, School of Health and Related Research, University of Sheffield, cSection of Clinical Pharmacology and Therapeutics, Department of Medicine and Pharmacology, University of Sheffield, dDirectorate of Policy and Public Health, Sheffield Health, Sheffield, UK PubMed articlesGoogle scholar articles
  • W W Yeo aMedical Care Research Unit, School of Health and Related Research, University of Sheffield, Regent Court, 30 Regent Street, Sheffield S1 4DA, UK, bSheffield Health Economics Group, School of Health and Related Research, University of Sheffield, cSection of Clinical Pharmacology and Therapeutics, Department of Medicine and Pharmacology, University of Sheffield, dDirectorate of Policy and Public Health, Sheffield Health, Sheffield, UK PubMed articlesGoogle scholar articles
  • P R Jackson aMedical Care Research Unit, School of Health and Related Research, University of Sheffield, Regent Court, 30 Regent Street, Sheffield S1 4DA, UK, bSheffield Health Economics Group, School of Health and Related Research, University of Sheffield, cSection of Clinical Pharmacology and Therapeutics, Department of Medicine and Pharmacology, University of Sheffield, dDirectorate of Policy and Public Health, Sheffield Health, Sheffield, UK PubMed articlesGoogle scholar articles
  1. Dr Pickin.
View Full Text

Citation

Pickin DM, McCabe CJ, Ramsay LE, et al
Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment
Heart 1999;82:325-332.

Publication history

  • Accepted April 6, 1999
  • First published September 1, 1999.
Online issue publication 
January 10, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

British Cardiac Society